PRDX1 and cancer: The difficulty of PRDX1 targeting in cancer in the clinical settings is related to the fact that chemical agents known to inhibit PRDX1, such as adenanthin [34,43], AI-44 [44], or frenolicin B [45], or the PRDX1-related antioxidant enzymatic system, such as SK053 [14] or AUR [13], are in most cases fairly unselective and/or do not possess satisfactory pharmacokinetics.